## Symic Bio to Present at Upcoming Conferences in Tokyo and Berlin

**SAN FRANCISCO, Oct. 23, 2017** – Symic Bio, a biopharmaceutical company developing novel matrix regulators, today announced that the company will present at the following conferences.

Sofinnova Japan Biopharma Partnering Conference

Presenter: Ken Horne, Chief Executive Officer

Date: Tuesday, Oct. 24, 2017

Time: 9:55 a.m. JST

Location: The Conrad Hotel, Tokyo

BIO-Europe 2017 – 23<sup>rd</sup> Annual International Partnering Conference

Presenter: Rinko Ghosh, President and Chief Business Officer

Date: Tuesday, Nov. 7, 2017

Time: 4:15 p.m. CET

Location: CityCube Berlin, Berlin

## **About Symic Bio**

Symic Bio is a biopharmaceutical company developing novel matrix regulators, a new category of therapeutics focused on matrix biology. These therapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules that play key regulatory roles within the extracellular matrix. Symic Bio currently has two clinical candidates: SB-030, which is targeting the prevention of peripheral vascular disease, and SB-061, directed at disease modification and pain management in the treatment of osteoarthritis. In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system. For additional information please visit the company's website at <a href="www.symic.bio">www.symic.bio</a>, LinkedIn page at <a href="www.linkedin.com/company/symic-bio">www.linkedin.com/company/symic-bio</a> or follow on Twitter at <a href="www.twitter.com/symicbio">www.twitter.com/symicbio</a>.

## **Investor Contacts**

Gitanjali Jain Ogawa The Trout Group (646) 378-2949 gogawa@troutgroup.com

## **Media Contacts**

David Schull or Rich Allan Russo Partners, LLC (212) 845-4271 (646) 942-5588 david.schull@russopartnersllc.com rich.allan@russopartnersllc.com